Approach to optic neuritis: An update

Swati Phuljhele, Sachin Kedar, Rohit Saxena

Research output: Contribution to journalReview articlepeer-review

Abstract

Over the past few years, there has been remarkable development in the area of optic neuritis. The discovery of new antibodies has improved our understanding of the pathology of the disease. Antiaquaporin4 antibodies and antimyelin oligodendrocytes antibodies are now considered as distinct entities of optic neuritis with their specific clinical presentation, neuroimaging characteristics, treatment options, and course of the disease. Similarly, there has been a substantial change in the treatment of optic neuritis which was earlier limited to steroids and interferons. The development of new immunosuppressant drugs and monoclonal antibodies has reduced the relapses and improved the prognosis of optic neuritis as well as an associated systemic disease. This review article tends to provide an update on the approach and management of optic neuritis.

Original languageEnglish (US)
Pages (from-to)2266-2276
Number of pages11
JournalIndian journal of ophthalmology
Volume69
Issue number9
DOIs
StatePublished - Sep 2021
Externally publishedYes

Keywords

  • Myelin oligodendrocytes
  • multiple sclerosis
  • neuromyelitis optica
  • optic neuritis

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint

Dive into the research topics of 'Approach to optic neuritis: An update'. Together they form a unique fingerprint.

Cite this